Furthermore, the next chapter transitions to predictive biomarkers, including RAS/BRAF/EGFR mutations, MSI/MMR, and receptor tyrosine-protein kinase erbB-2 (HER2), which guides therapeutic decision-making in CRC management. This evidence concerns the gene ERBB2 and colorectal carcinoma.